Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune skin disorder bullous pemphigoid (BP). The US Food ...

Year to date, shares of Sanofi have lost 4% against the industry’s growth of 1.4%. Image Source: Zacks Investment Research Per the expanded collaboration agreement, Sanofi and SK bioscience will ...

The vaccines division of sanofi aventis group. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the ...